BridgeBio Pharma
BBIO
179 hedge funds and large institutions have $1.1B invested in BridgeBio Pharma in 2022 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 55 increasing their positions, 71 reducing their positions, and 25 closing their positions.
173% more call options, than puts
Call options by funds: $2.08M | Put options by funds: $761K
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
4% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 25
1% less funds holding
Funds holding: 181 → 179 (-2)
1.23% less ownership
Funds ownership: 97.96% → 96.72% (-1.2%)
23% less repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 71
24% less capital invested
Capital invested by funds: $1.44B → $1.1B (-$342M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$10.2M |
| 2 |
State Street
Boston,
Massachusetts
|
+$8.64M |
| 3 |
Barclays
London,
United Kingdom
|
+$8.38M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.62M |
| 5 |
BlackRock
New York
|
+$4.81M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$10.4M |
| 2 |
Millennium Management
New York
|
-$10.4M |
| 3 |
GCM
Graham Capital Management
Rowayton,
Connecticut
|
-$6M |
| 4 |
TCM
Tang Capital Management
San Diego,
California
|
-$5.82M |
| 5 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$4.97M |
BBIO Hedge Fund Activity: Q4 2022 in Review
179 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in BridgeBio Pharma (BBIO) for Q4 2022, worth a combined $1.1B — down 24% from $1.44B a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of BBIO and 24 opened new positions — a net loss of 1 holder — while 71 trimmed existing stakes and 55 added.
The largest buyer was Citadel Advisors, adding an estimated $10.2M. The largest seller was Great Point Partners, exiting entirely with an estimated $10.4M sold.
- 179 institutional investors held BridgeBio Pharma (BBIO) as of Q4 2022, down from 181 in Q3 2022.
- Funds reported $1.1B of BridgeBio Pharma stock for Q4 2022, down 24% quarter-over-quarter.
- 24 funds opened new BridgeBio Pharma positions in Q4 2022 and 25 closed out, a net change of -1 holder.
- The largest BridgeBio Pharma buyer in Q4 2022 was Citadel Advisors, an estimated $10.2M added.
- The largest BridgeBio Pharma seller in Q4 2022 was Great Point Partners, an estimated $10.4M sold.
Based on aggregated 13F filings for Q4 2022.